Sanofi-Aventis has made a hostile offer to acquire Genzyme for $18.5 billion, or $69 per share, and the latter has urged shareholders to refrain from acting on the unsolicited bid. "Genzyme's refusal to take part in constructive discussions has led Sanofi-Aventis to put forward its offer directly to shareholders," Sanofi said.

Full Story:

Related Summaries